A detailed history of Clarius Group, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Clarius Group, LLC holds 7,301 shares of GILD stock, worth $610,436. This represents 0.04% of its overall portfolio holdings.

Number of Shares
7,301
Previous 7,522 2.94%
Holding current value
$610,436
Previous $550,000 9.09%
% of portfolio
0.04%
Previous 0.04%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 11, 2024

SELL
$63.15 - $72.88 $13,956 - $16,106
-221 Reduced 2.94%
7,301 $500,000
Q1 2024

Apr 17, 2024

SELL
$71.58 - $87.29 $165,994 - $202,425
-2,319 Reduced 23.56%
7,522 $550,000
Q4 2023

Jan 29, 2024

BUY
$73.27 - $83.09 $26,377 - $29,912
360 Added 3.8%
9,841 $797,000
Q3 2023

Oct 19, 2023

SELL
$73.94 - $80.67 $263,152 - $287,104
-3,559 Reduced 27.29%
9,481 $710,000
Q2 2023

Aug 09, 2023

BUY
$76.01 - $86.7 $2,584 - $2,947
34 Added 0.26%
13,040 $1 Million
Q1 2023

Apr 17, 2023

BUY
$77.31 - $88.08 $84,886 - $96,711
1,098 Added 9.22%
13,006 $1.08 Million
Q4 2022

Jan 25, 2023

BUY
$62.32 - $89.47 $57,521 - $82,580
923 Added 8.4%
11,908 $1.02 Million
Q3 2022

Oct 24, 2022

BUY
$59.54 - $68.01 $277,694 - $317,198
4,664 Added 73.79%
10,985 $678,000
Q2 2022

Aug 10, 2022

SELL
$57.72 - $65.01 $235,151 - $264,850
-4,074 Reduced 39.19%
6,321 $391,000
Q4 2021

Feb 02, 2022

BUY
$64.88 - $73.64 $48,465 - $55,009
747 Added 7.74%
10,395 $755,000
Q3 2021

Oct 18, 2021

BUY
$67.69 - $73.03 $23,285 - $25,122
344 Added 3.7%
9,648 $674,000
Q2 2021

Aug 06, 2021

BUY
$63.47 - $69.35 $1,269 - $1,387
20 Added 0.22%
9,304 $641,000
Q1 2021

Apr 27, 2021

BUY
$60.0 - $68.46 $214,380 - $244,607
3,573 Added 62.56%
9,284 $600,000
Q4 2020

Jan 15, 2021

SELL
$56.65 - $64.55 $52,004 - $59,256
-918 Reduced 13.85%
5,711 $333,000
Q3 2020

Oct 09, 2020

SELL
$62.1 - $78.08 $258,460 - $324,968
-4,162 Reduced 38.57%
6,629 $419,000
Q2 2020

Jul 08, 2020

BUY
$72.34 - $84.0 $111,258 - $129,192
1,538 Added 16.62%
10,791 $830,000
Q1 2020

Apr 24, 2020

BUY
$62.63 - $80.22 $73,339 - $93,937
1,171 Added 14.49%
9,253 $692,000
Q4 2019

Jan 22, 2020

BUY
$61.62 - $67.78 $35,246 - $38,770
572 Added 7.62%
8,082 $518,000
Q3 2019

Oct 23, 2019

BUY
$62.51 - $69.0 $71,261 - $78,660
1,140 Added 17.9%
7,510 $476,000
Q2 2019

Aug 02, 2019

BUY
$61.87 - $69.38 $76,347 - $85,614
1,234 Added 24.03%
6,370 $430,000
Q1 2019

May 14, 2019

BUY
$62.53 - $70.05 $106,488 - $119,295
1,703 Added 49.61%
5,136 $334,000
Q4 2018

Feb 11, 2019

BUY
$60.54 - $79.0 $207,833 - $271,207
3,433 New
3,433 $215,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $105B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Clarius Group, LLC Portfolio

Follow Clarius Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clarius Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clarius Group, LLC with notifications on news.